Skip to main content

Advertisement

SpringerLink
Log in

Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

  • Osteoporosis and Cancer (P Clezardin and G van der Pluijm, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Body J-J. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21 Suppl 7:vii180–5.

    PubMed  Google Scholar 

  2. Vanderwalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. Cancer J Clin. 2011;61(3):139–56. It shows how cancer may cause decreases in bone mineral density and an increased risk of debilitating fracture.

    Article  Google Scholar 

  3. Pfeilschifter J, DielI J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–93.

    CAS  PubMed  Google Scholar 

  4. Reuss-Borst M, Hartmann U, Scheede C, Weiß J. Prevalence of osteoporosis among cancer patients in Germany. Osteoporos Int. 2012;23(4):1437–44. Higher prevalence of osteoporosis in cancer patients—this article is important as it mentions the many cases of osteoporosis in cancer patients.

    Article  CAS  PubMed  Google Scholar 

  5. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: breast cancer, version 3. www.nccn.org. Accessed 15 May 2014

  6. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: prostate cancer, version 2. www.nccn.org. Accessed 15 May 2014

  7. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288(15):1889–97.

    Article  PubMed  Google Scholar 

  8. Cameron DA, Douglas S, Brown JE, Anderson RA. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat. 2010;123(3):805–14.

    Article  CAS  PubMed  Google Scholar 

  9. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990;61(2):308–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.

    Article  CAS  PubMed  Google Scholar 

  11. Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Nat Compr Cancer Netw. 2009;7(7):S1–29. quiz S30.

    CAS  Google Scholar 

  12. Kodama H, Nose M, Niida S, et al. Essential role of macrophage colony stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 1991;173:1291–4.

    Article  CAS  PubMed  Google Scholar 

  13. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.

    Article  CAS  PubMed  Google Scholar 

  14. Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2010;2012(6):287–303. Role of denosumab in prevention of vertebral fractures and increasing bone mineral density in cancer treatment-induced bone loss.

    Google Scholar 

  15. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.

    Article  CAS  PubMed  Google Scholar 

  16. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline, update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Am Soc Clin Oncol J Clin Oncol. 2010;28(23):3784–96.

    Article  Google Scholar 

  17. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours, recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.

    Article  CAS  PubMed  Google Scholar 

  18. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336–42.

    Article  CAS  PubMed  Google Scholar 

  20. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416–24.

    Article  PubMed  Google Scholar 

  21. Hines SL, Mincey BA, Sloan JA, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009;27:1047–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12:R24.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967–75.

    Article  PubMed  Google Scholar 

  24. Ishizaka K, Machida T, Kobayashi S, et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol. 2007;14:1071–5.

    Article  CAS  PubMed  Google Scholar 

  25. Kearns AE, Northfelt DW, Dueck AC, et al. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010;18:321–8.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Cluett J. Side effects of bisphosphonate medications. 2012. http://orthopaedics.about.com/od/oateoporosistreatment/p/bisphophanatesideeffects. List some common side effects of bisphosphonates. This helps in identifying those side effects while a patient is on drug.

  27. Merck, Co I. Fosamax (alendronate sodium) tablets and oral solution full prescribing information. 2011.

  28. Warner Chilcott Company L. Actonel (risedronate sodium) tablets full prescribing information. 2011.

  29. Roche Laboratories I. Boniva (ibandronate sodium) tablets and solution for infection, full prescribing information. 2011.

  30. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.

    Article  CAS  PubMed  Google Scholar 

  31. Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009;117:603–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972–8. discussion 978.

    Article  CAS  PubMed  Google Scholar 

  33. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26:4739–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–8.

    Article  CAS  PubMed  Google Scholar 

  35. Bertoldo F, Tonini G, Vincenzi B, et al. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. Nat Rev Clin Oncol. 2009;6:191–2.

    Article  CAS  PubMed  Google Scholar 

  36. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77–85.

    Article  CAS  PubMed  Google Scholar 

  37. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21:2188–94.

    Article  CAS  PubMed  Google Scholar 

  38. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47:683–9. This study is relevant to prove benefits of zoledronic acid.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271–7.

    Article  CAS  PubMed  Google Scholar 

  40. Hershman DL, McMahon DJ, Crew KD, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010;95:559–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Hines SL, Sloan JA, Atherton PJ, et al. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010;19:92–6.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Campbell SC, Bhoopalam N, Moritz TE, et al. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology. 2010;75:1138–43.

    Article  PubMed  Google Scholar 

  43. Casey R, Gesztesi Z, Rochford J. Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol. 2010;17:5170–7.

    PubMed  Google Scholar 

  44. Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66:1054–9.

    Article  PubMed  Google Scholar 

  45. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

    Article  CAS  PubMed  Google Scholar 

  46. Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182:2257–64.

    Article  CAS  PubMed  Google Scholar 

  47. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.

    Article  CAS  PubMed  Google Scholar 

  48. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008;112:1001–10.

    Article  CAS  PubMed  Google Scholar 

  49. Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) injection. 2011.

  50. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–6.

    Article  CAS  PubMed  Google Scholar 

  51. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. GTX I. GTx provides corporate update and reports first quarter 2011 financial results. 2011. http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle_print&ID=1561101&highlight=. Accessed 17 May 2014

  54. Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185:17–23.

    Article  CAS  PubMed  Google Scholar 

  55. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–5.

    Article  CAS  PubMed  Google Scholar 

  56. Novartis Pharmaceuticals Corporation. Miacalcin (calcitonin salmon) (injection or nasal spray) full prescribing information. 2011.

  57. Eli Lilly and Company. Forteo (teriparatide injection) full prescribing information. 2010.

  58. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.

    Article  CAS  PubMed  Google Scholar 

  59. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510–6.

    Article  CAS  PubMed  Google Scholar 

  60. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.

    Article  CAS  PubMed  Google Scholar 

  61. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009;182:2670–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Smith MR, Saad F, Egerdie B, et al. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011;26:2827–33. There is rapid decline in bone turnover markers in patient on androgen deprivation therapy for prostate cancer receiving denosumab. That may be relevant to monitor the response of denosumab.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118:81–7.

    Article  CAS  PubMed  Google Scholar 

  64. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health-Syst Pharm. 2006;63:534–46.

    Article  CAS  PubMed  Google Scholar 

  65. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Nat Compr Cancer Netw. 2009;7(3):S1–32. quiz S33–5.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

A. Garg, K. Leitzel, S. Ali, and A. Lipton all declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Penn State Hershey Medical Center, 500 University Drive, Hershey, PA, 17033, USA

    Ashwani Garg, Kim Leitzel, Suhail Ali & Allan Lipton

  2. Lebanon VA Medical Center, Lebanon, PA, USA

    Suhail Ali

Authors
  1. Ashwani Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim Leitzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suhail Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashwani Garg.

Additional information

This article is part of the Topical Collection on Osteoporosis and Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garg, A., Leitzel, K., Ali, S. et al. Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss. Curr Osteoporos Rep 13, 73–77 (2015). https://doi.org/10.1007/s11914-014-0252-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-014-0252-x

Keywords

Search

Navigation